Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01515358 | A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants | PHASE1 | COMPLETED | 18 | — | — | Feb 1, 2012 | May 1, 2012 | May 31, 2012 | 1 | Singapore |
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose. |
| LY3000328 | EXPERIMENTAL | Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered orally |
| LY3000328 | DRUG | Administered orally |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination